Each vial (5 ml) contains Doxorubicin Hydrochloride USP 10 mg Sterile Injectable Solution for Intravenous use.
Adjuvant Breast Cancer:
The recommended dose is 60 mg/m2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.
Metastatic Disease, Leukemia, or Lymphoma
i) The recommended dose of Doxorubicin HCI when used as a single agent is 60 to 75 mg/m2 intravenously every 21 days.
ii) The recommended dose when administered in combination with other chemotherapy drugs, is 40 to 75 mg/m2 intravenously every 21 to 28 days.
iii) Consider use of the lower Doxorubicin dose in the recommended dose range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients. iv) Cumulative doses above 550 mg/m2 are associated with an increased risk of cardiomyopathy. Or, as directed by the registered physicians. Please see prescribing description for more information.